Novo Nordisk A/S (NVO · NYSE)
NVO · MARKET VIEW
Market view · as of Sep 7, 2026
Revenue (TTM)
$329.43B
+2.1% YoY
Gross margin
82.0%
EPS (latest q)
$0.96
vs $0.82 est · beat
52-wk position
45.8%
-23.7% vs 52w high · -0.1% 1mo
Price (last ~year)
Novo Nordisk (NVO) faces recent analyst downgrades citing slowing GLP-1 prescription trends, even as the company expands its market reach with the launch of oral Wegovy in Germany. The pharmaceutical firm reported a 2.1% year-over-year revenue increase to $329.43 billion TTM, though earnings have declined 20.6% over the same period. Shares are currently priced at $46.60, reflecting a 23.7% decline from the 52-week high against a market capitalization of $205.97 billion.
Valuation
- Market cap
- $205.97B
- P/E
- 11.45
- PEG
- 3.36
- P/B
- 6.12
- P/S
- 0.625
- EV/EBITDA
- 9.66
- Beta
- 0.344
- Analyst target
- $47.16
Quality & returns
- Gross margin
- 82.0%
- Operating margin
- 42.5%
- Profit margin
- 35.3%
- ROE
- 59.8%
- ROA
- 18.7%
Price movement
- Last
- $46.60
- 1-month
- -0.1%
- 3-month
- +10.3%
- RSI (14)
- 58
- vs SMA200
- +3.3%
- 52-wk position
- 45.8% -23.7% vs high
Quarterly trajectory
Revenue by quarter (oldest → newest)
| Quarter | Revenue | Op income | Net income | EBITDA |
|---|---|---|---|---|
| 2026-06-30 | $78.49B | $27.06B | $20.99B | $38.68B |
| 2026-03-31 | $96.82B | $59.62B | $48.56B | $69.21B |
| 2025-12-31 | $79.14B | $31.74B | $26.89B | $39.75B |
| 2025-09-30 | $74.98B | $23.68B | $20.01B | $33.27B |
Recent news
- Bullish Novo Nordisk Foundation to build $62M quantum chip plant in Copenhagen · 2026-09-04
- Somewhat-Bearish Citi flags GLP-1 prescription slowdown at Novo Nordisk, reiterates 'sell' · 2026-09-02
- Bearish Novo Nordisk A/S : Deutsche Bank reiterates its Sell rating · 2026-09-02
- Somewhat-Bullish Novo Nordisk launches Wegovy weight-loss pill in Germany · 2026-09-02
- Bearish Ozempic maker Novo Nordisk downgraded to sell following 70% stock-price dive from peak · 2026-08-27
- Neutral Eli Lilly vs Novo Nordisk: One Winner in The Weight-Loss Drug Gold Rush · 2026-08-25
Sources this view read
- fundamentals Company overview & valuation (Alpha Vantage OVERVIEW)
- filing Quarterly financial statements (Alpha Vantage INCOME/BALANCE/CASH)
- earnings Reported earnings history (Alpha Vantage EARNINGS)
- prices Adjusted daily prices (Alpha Vantage TIME_SERIES_DAILY_ADJUSTED)